By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


SEARCH JOBS


Industry
Biotechnology






Company News
FDA Delays Decision on Sarepta (SRPT)'s Muscle-Wasting Disorder Drug 2/8/2016 7:19:13 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2/3/2016 10:18:49 AM
With Snowmageddon Predicted for East Coast, FDA Postpones Meeting Over Sarepta (SRPT)’s DMD Drug 1/21/2016 5:53:46 AM
FDA Turns Down Both BioMarin (BMRN) and Sarepta (SRPT)’s DMD Drug Applications, Stocks Plunge 1/15/2016 6:00:13 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/5/2016 11:44:00 AM
Sarepta (SRPT) Announces FDA Advisory Committee Meeting To Review Eteplirsen As A Treatment For Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 12/18/2015 11:07:07 AM
Biotechs Like Dyax (DYAX), Sarepta (SRPT) are Amongst Massachusetts' Top Performing Stocks for 2015 12/15/2015 6:45:20 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/2/2015 1:22:59 PM
Former Sarepta (SRPT) CEO's Feelings About BioMarin (BMRN)'s Drug Panel 11/30/2015 6:52:56 AM
Sarepta (SRPT) Announces Publication Of Positive Long-Term Safety And Efficacy Data For Eteplirsen In The Annals Of Neurology 11/17/2015 10:24:06 AM
12345678910...
//-->